SCYNEXIS names Steven K. Burke to board as ADPKD program advances

SCYNEXIS, Inc. (NASDAQ: SCYX) appointed Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026.¹

Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease.¹ He currently serves at Akebia Therapeutics, where he has worked since 2019, and has served as its Senior Vice President, Chief Research and Development Officer and Chief Medical Officer since 2021.¹ At Akebia, he has had a leadership role in the development of Vafseo (vadadustat) for anemia due to chronic kidney disease and has supported Auryxia (ferric citrate).¹ Earlier in his career, Dr. Burke served as Senior Vice President and Chief Medical Officer of Proteon Therapeutics, Inc. from 2006 to 2019 and in senior positions at several other biotechnology companies including Genzyme Inc.¹

Board chairman Guy Macdonald noted the appointment comes as the company works on its ADPKD candidate, saying 2026 has been a transformative year for SCYNEXIS following the acquisition of SCY-770, a promising drug candidate in development for Autosomal Dominant Polycystic Kidney Disease, according to the company.¹ Burke himself said this is a very exciting time to join the SCYNEXIS Board as the Company prepares to enter Phase 2 with SCY-770, according to Dr. Burke.¹

The filing's forward-looking statements section describes the timing and results of the Company's anticipated Phase 2 proof-of-concept clinical study evaluating SCY-770¹ as subject to risks and uncertainty, rather than a confirmed timeline.

Burke's compensation package includes an annual retainer of $45,000, an annual retainer of $5,000 for service as a member of the Nominating and Corporate Governance Committee, an initial stock option grant to purchase 5,750 shares with an exercise price of $4.46, and an initial restricted stock unit grant to acquire 5,750 shares.¹